Huahui Health, BeOne Strike $2B HH160 Oncology Deal
BEIJING, CHINA, April 27, 2026 Huahui Health has announced a global exclusive option, license, and collaboration agreement with BeOne...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BEIJING, CHINA, April 27, 2026 Huahui Health has announced a global exclusive option, license, and collaboration agreement with BeOne...
FREDERICK, MARYLAND, April 30, 2026 Theradaptive has received U.S. Food and Drug Administration (FDA) authorization to advance its OASIS...
